{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-050607","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2026-07-29T20:07:19+00:00","discovered_at":"2026-07-29T20:08:00.541498+00:00","generated_at":"2026-07-29T20:08:15.177098+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Corcept Q2 revenue up 32% to $256M; raises FY2026 guidance to $1.1-1.2B","bullets":["Revenue $256.1M (+32% YoY); net income $43.0M ($0.36 diluted EPS) vs $35.1M ($0.29) in Q2 2025.","Lifyorli (relacorilant) generated $47.6M in first quarter of availability; over 1,300 patients started treatment.","FY2026 revenue guidance increased to $1.1-1.2 billion.","NDA for relacorilant in Cushing's syndrome resubmitted; PDUFA date December 17, 2026.","Cash and investments $544.6M at June 30, 2026, up from $515.4M at March 31, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-050607","json":"https://secwatch.observer/filing/0001628280-26-050607.json","markdown":"https://secwatch.observer/filing/0001628280-26-050607.md","text":"https://secwatch.observer/filing/0001628280-26-050607.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000162828026050607/0001628280-26-050607-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000162828026050607/cort-20260729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-29T20:08:15.177098+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}